나노바이오틱스(NBTX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $33.55 (-6.49%), 시가총액 $2.50B, 52주 최저~최고 $3.64 ~ $55.07.
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
나노바이오틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
나노바이오틱스의 현재 주가는 $33.55 (-6.49%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
나노바이오틱스의 시가총액은 약 $2.50B입니다.
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3